FDA.reportPublic FDA data

0.05 ML brolucizumab-dbll 120 MG/ML Prefilled Syringe

RxCUI
2602276
RxNorm name
0.05 ML brolucizumab-dbll 120 MG/ML Prefilled Syringe
Display name
0.05 ML brolucizumab-dbll 120 MG/ML Prefilled Syringe
Full name
0.05 ML brolucizumab-dbll 120 MG/ML Prefilled Syringe
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:00

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761125Beovubrolucizumab-dbll351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BEOVUBROLUCIZUMABNovartis Pharmaceuticals Corporation5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d2025-11-03Warnings, Adverse reactionsExact identifier
rxcui: 2602276

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d0.05 ML brolucizumab-dbll 120 MG/ML Prefilled SyringeSCD16These highlights do not include all the information needed to use BEOVU safely and effectively. See full prescribing information for BEOVU. BEOVU ® (brolucizumab-dbll) injection, for intravitreal use Initial U.S. Approval: 201920251103
5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3dbrolucizumab-dbll 6 MG in 0.05 ML Prefilled SyringePSN16These highlights do not include all the information needed to use BEOVU safely and effectively. See full prescribing information for BEOVU. BEOVU ® (brolucizumab-dbll) injection, for intravitreal use Initial U.S. Approval: 201920251103
5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3dbrolucizumab-dbll 120 MG/ML per 0.05 ML Prefilled SyringeSY16These highlights do not include all the information needed to use BEOVU safely and effectively. See full prescribing information for BEOVU. BEOVU ® (brolucizumab-dbll) injection, for intravitreal use Initial U.S. Approval: 201920251103
5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3dbrolucizumab-dbll 6 MG per 0.05 ML Prefilled SyringeSY16These highlights do not include all the information needed to use BEOVU safely and effectively. See full prescribing information for BEOVU. BEOVU ® (brolucizumab-dbll) injection, for intravitreal use Initial U.S. Approval: 201920251103